Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | CHIEF FINANCIAL OFFICER | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,000 |
Last balance in matching sequence
After 2026-09-17 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-09-17 · Exercise / conversion · Acquired 3,982 · Balance 44,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 2 · 2026-09-17 · Sale · Disposed 3,535 · Balance 40,483 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 3 · 2026-09-17 · Sale · Disposed 2,194 · Balance 38,289 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 4 · 2026-09-17 · Sale · Disposed 289 · Balance 38,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2034-02-13 | Direct | 181,018 |
Reported balance
After 2026-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-17 · Exercise / conversion · Disposed 3,982 · Balance 181,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,383 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · derivative · entry 9 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,120 Underlying: Common Stock · 9,383 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 9,383 | $15.01 | $140,838.83 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · nonDerivative · entry 6 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 9,383 | $2.48 | $23,269.84 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · nonDerivative · entry 5 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · derivative · entry 8 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,503 Underlying: Common Stock · 20 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 20 | $15.00 | $300.00 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 20 | $2.48 | $49.60 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 28, 2023 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,467 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · derivative · entry 7 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,523 Underlying: Common Stock · 2,467 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2023 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,467 | $15.07 | $37,188.05 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 28, 2023 Filed Jan 3, 2024 00:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 2,467 | $2.48 | $6,118.16 |
DisclosureSEC source: 0001209191-24-000255 · doc4.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 22:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-23-059814 · doc4.xml · derivative · entry 6 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,990 Underlying: Common Stock · 100 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 22:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001209191-23-059814 · doc4.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 22:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 100 | $2.48 | $248.00 |
DisclosureSEC source: 0001209191-23-059814 · doc4.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 22:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,030 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-23-059814 · doc4.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 261,090 Underlying: Common Stock · 1,030 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 22:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,030 | $15.07 | $15,524.98 |
DisclosureSEC source: 0001209191-23-059814 · doc4.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 22:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,030 | $2.48 | $2,554.40 |
DisclosureSEC source: 0001209191-23-059814 · doc4.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 04, 2023 Filed Apr 7, 2023 00:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 206,000 | $0.00 Strike: $22.75 | $0.00 |
DisclosureSEC source: 0001209191-23-023677 · doc4.xml · derivative · entry 1 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,000 Underlying: Common Stock · 206,000 shares Expires 2033-04-04 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantEmployee Stock Option (right to buy) · Derivative | 262,120 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001209191-23-013494 · doc4.xml · derivative · entry 1 Hohl Benjamin · CIK 0001882764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,120 Underlying: Common Stock · 262,120 shares Expires 2031-08-02 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3)) F3 · price: (continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on August 2, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.